Generic drugmaker Strides Pharma Science has announced that its subsidiary Strides Pharma Global has received the FDA’s approval for its amantadine hydrochloride softgel capsules for the treatment of symptoms of infection caused by influenza A.

The product, which is bioequivalent to Endo Pharmaceuticals’ Symmetrel — an antiviral drug and a dopamine promoter — will be manufactured at the Strides’ facility in Bangalore, India.

Symmetrel is also used to treat symptoms of Parkinson’s disease and Parkinson’s-like symptoms caused by certain medications.